Emergent BioSolutions: The Quarter That Beat the Forecast, and the Write-Down That Buried the Headline
Emergent BioSolutions once made headlines as the company the U.S. government called when it needed vaccines fast. At its peak...
Corcept Therapeutics: One Drug Fading, One Just Born, and a Stock Priced for Neither
For most of its life, Corcept Therapeutics was essentially a one-drug company. Korlym, its mifepristone pill for Cushing's syndrome (a...
Evidence Sheet: Biohaven (BHVN)
The standing BullScope yardsticks for Biohaven, computed from official filings and refreshed with each new edition.
Biogen’s stock has climbed 65% in a year. Its earnings have not.
Five years ago, Biogen bet the company on a drug most neurologists did not believe in. Aduhelm, its controversial Alzheimer's...
Zoetis: The Market’s Collapse Thesis vs. What the Filings Show
For most of its first decade as a public company, Zoetis was the kind of business that made investors feel...
Evidence Sheet: Blackrock Virginia Municipal Bond Trust (BHV)
The standing BullScope yardsticks for Blackrock Virginia Municipal Bond Trust, computed from official filings and refreshed with each new edition.
Arrowhead’s Burning Runway Meets a Crowded Pipeline: Reading the Q3 2026 Filing
For most of its life, Arrowhead Pharmaceuticals was a company that spent money and promised science. It had no approved...
Apple at $336: The Business Is Growing. The Price Assumes It Never Stops.
First, the shape of it Apple's filed numbers show a business that earned more per dollar of sales in fiscal...
Collegium Pharmaceutical: A Business Growing Into a Price That Has Already Left
The stock is down more than half from its 52-week high. The company just raised its full-year revenue guidance. Both...
Evidence Sheet: Caterpillar (CAT)
The standing BullScope yardsticks for Caterpillar, computed from official filings and refreshed with each new edition.
BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.